Drug facts

Molecule

Acetaminophen and Oxycodone

Generics already compete: 17 makers on the market. 51 A-rated products from 16 makers substitute at the counter.

Xartemis XR was first approved by the FDA on 03/11/2014 under NDA 204031; the application holder is Mallinckrodt Inc. The Orange Book lists NDA 204031 as discontinued.

The latest NADAC for OXYCODONE-ACETAMINOPHEN 7.5-325 MG TABLET is $0.18 per unit (as of 10/28/2026).

Holder Mallinckrodt IncApplication NDA 204031Approved 03/11/2014

01Patents and exclusivity

When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.

2,024days until the latest patent expires

ExclusivityPatent onlyOpen to generics
Today
Approved03/11/2014
Last patent05/16/2032
2015201820212024202720302033
Latest patent
05/16/2032Xartemis XR
Orange Book

02Competition

Generics
17 generic makers
Orange Book
Staged generics
1 passed FDA review, awaiting market entry
FDA
First generic approved
before 1982
Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Acetaminophen and Oxycodone profile.See what is included

03Supply and price

FDA drug shortage
ClearNot on the current shortage list
FDA shortages
NADAC
$0.18 per unitOXYCODONE-ACETAMINOPHEN 7.5-325 MG TABLET, mid-priced of 6 strengths, as of 10/28/2026
CMS NADAC
Latest recall
12/16/2025Class II, Oxycodone Hydrochloride and Acetaminophen, Specgx, LLC
FDA enforcement

04Product

Application holder
Mallinckrodt Inc
Orange Book
Application
NDA 204031
Orange Book
First approved
03/11/2014
Orange Book
Dosage forms
solution; tablet
Routes
oral
Other brand names
OxycetPercocet
Status
NDA 204031 discontinued
Orange Book

Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.